Alzheimer's Disease and Mild Cognitive Impairment

Current evidence suggests ~80% of patients with Mild Cognitive Impairment (MCI) will eventually develop Alzheimer's disease (AD). Many times a trial is stated to be for Early AD which really covers both MCI and mild stage of AD. These trials involve novel approaches and new trial designs with the hope of more rapidly finding new answers for these conditions.

Condition(s) Type of Drug Phase Add-On Placebo Duration Open Label Extension
MCI and Mild AD Intravenous anti-tau antibody III Yes 33% 18 months 5 years
MCI and Mild AD Oral BACE inhibitor III Yes 50% 48 weeks 1+ years
MCI and Mild AD Counterpulsation device III Yes 50% 24 weeks 1 year
Agitation in AD Oral 5HT2A antagonist III Yes 50% 8 weeks None
Agitation in AD Oral combination of two approved drugs III Yes 33% 5 weeks None

Also see Imaging.

Response Form

If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!

- Stephen S. Flitman, MD, Medical Director

Your Name
Name of Patient
Email Address
Your Telephone
Best Time to Call
Comments
 Ready?